

Insights: Publications

Costly Deals – New FTC rules on patent licenses in M&As have caused a storm. Two experts discuss why they could be bad for the pharma business

IPPro Life Sciences

February 20, 2014

In the U.S., the FTC has broadened the type of patent licences that have to be reported following mergers and acquisitions. In your opinion, how onerous are the 6 November Premerger Notification Rules, and why?